Welcome to our dedicated page for Galectin Therapeutics news (Ticker: GALT), a resource for investors and traders seeking the latest updates and insights on Galectin Therapeutics stock.
Galectin Therapeutics Inc (NASDAQ: GALT) pioneers novel carbohydrate-based therapies targeting galectin-3 proteins to address fibrotic diseases and cancers. This page serves as the definitive source for verified company announcements, including clinical trial milestones, regulatory updates, and strategic partnerships.
Investors and researchers will discover timely updates on adaptive clinical programs for conditions like MASH cirrhosis, oncology developments, and scientific advancements in galectin inhibition technology. All content is curated to provide actionable insights without speculative commentary.
The repository includes earnings reports, FDA communications, research collaborations, and therapeutic pipeline progress. Bookmark this page for streamlined access to GALT's latest developments in carbohydrate-based drug innovation and fibrotic disease research.
Galectin Therapeutics (NASDAQ: GALT) reported its Q1 2024 financial results and provided a business update. The NAVIGATE Phase 2b/3 trial of belapectin in liver cirrhosis due to MASH continues as planned, with an interim top-line readout expected late Q4 2024 after a positive fifth DSMB meeting.
Q1 financials show $23.6M in cash with an additional $10M available from a new line of credit. R&D expenses decreased to $8.1M from $8.8M YoY, while G&A expenses increased slightly to $1.6M from $1.5M. The net loss remained constant at $11.5M or ($0.19) per share YoY.
Corporate updates include the appointment of Dr. Khurram Jamil as VP of Clinical Development. The company mourns the loss of Dr. Stephen A. Harrison, a key figure in the belapectin program.
Galectin Therapeutics Inc. (NASDAQ: GALT) will participate in the H.C. Wainwright BioConnect Conference, presenting at the fireside chat on May 20, 2024, at 4:00 PM ET at the Nasdaq World Headquarters in New York City. The management team will be available for one-on-one meetings, and a webcast link will be provided on the Company's website.
FAQ
What is the current stock price of Galectin Therapeutics (GALT)?
What is the market cap of Galectin Therapeutics (GALT)?
